Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
"Fantastic service, Really helpful & always able to source products that we need at very competitive prices. Would thoroughly recommend to any Veterinary Practice"
"Raman Pharma have been invaluable in sourcing drugs that are out of stock elsewhere. Delivery is rapid, costs are good and the customer service provided by Dhruv is excellent. I would definitely recommend this company and its services to others."
Class 2 MHRA medicines recall – Ranitidine Effervescent Tablets 150mg and 300mg (Teva UK Limited trading as ratiopharm GmbH) Drug alert number: EL (19)A/27 Date issued: 17 October 2019 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 2 medicines recall for: Ranitidine Effervescent Tablets 150mg and 300mg (Teva UK Limited trading...
Further to our news story Temporary parallel export ban issued to ensure continued supply of medicines the Department of Health and Social Care (DHSC) and the Medicines and Healthcare products Regulatory Agency (MHRA) has announced that a further four medicines are to be added to the list of medicines which must not be parallel exported...
Community pharmacy contractors may now like to consider completing the dementia-friendly environment checklist and action plan to meet the quality criterion, if they have not already done so. To meet the dementia-friendly environment checklist quality criterion, contractors are required to have completed, on the day of the declaration, a specified dementia-friendly environment checklist and have...
Class 4 MHRA drug alert – Xonvea 10 mg/10 mg gastro-resistant tablets (Alliance Pharmaceuticals Limited) Drug alert number: EL (19)A/26 Date issued: 16 October 2019 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 pharmacy level caution in use for: Xonvea 10 mg/10 mg gastro-resistant tablets (Alliance Pharmaceuticals Limited) Alliance Pharmaceuticals...
We have been made aware that, due to the NHS Urgent Medicine Supply Advanced Service (NUMSAS) and the Digital Minor Illness Referral Service (DMIRS) finishing on 28th October 2019 and the Community Pharmacist Consultation Service (CPCS) starting on 29th October 2019, that this has caused some confusion for community pharmacy contractors when updating their DoS...
Class 4 MHRA drug alert – Rifadin (rifampicin) 150mg Capsules (Aventis Pharma Limited t/a Sanofi) Drug alert number: EL (19)A/25 Date issued: 16 October 2019 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 pharmacy level caution in use for: Rifadin (rifampicin) 150mg Capsules – PL 04425/5915R Aventis Pharma Limited t/a...
All oral formulations of Ranitidine are anticipated to be out of stock, with no date for resupply until further notice. The following oral presentations of Ranitidine are affected: Ranitidine 75mg, 150mg and 300mg tablets Ranitidine 150mg and 300mg effervescent tablets Ranitidine 150mg/5ml oral solution Ranitidine 75mg/5ml oral solution The Supply Disruption Alert (SDA/2019/005) issued by DHSC...
PSNC has outlined how community pharmacies can contribute to the prevention agenda in its response to a government consultation. Earlier this year, the Government set out a green paper, Advancing our health: prevention in the 2020s, outlining policy ideas to help prevent ill-health. The paper then opened to consultation in the form of an online...
Following the announcement of the first Serious Shortage Protocols (SSPs) issued on 3rd October 2019 for Fluoxetine capsules, PSNC has been working with NHS Business Services Authority (NHSBSA) to understand if claims are being submitted in accordance with SSP endorsement guidance. During the month of October, NHSBSA has received a number of EPS messages which...
Self Care Week, which is an annual national awareness week that focuses on providing support for self care across communities and families, will be running again this year on 18-24th November 2019. The campaign aims to provide people-facing organisations such as community pharmacies with a focus to hold a targeted campaign to support people to take care...
Teva UK Ltd is recalling unexpired stock of certain batches of 2 types of Ranitidine medicines used to treat conditions such as heartburn and stomach ulcers.
Teva UK Limited trading as ratiopharm GmbH is recalling all unexpired stock of Ranitidine Effervescent Tablets from pharmacies.
Department of Health and Social Care and MHRA register of licensed wholesale distribution sites (human and veterinary).
Parallel import licenses granted in September 2019
Marketing authorisations granted in September 2019
Sets out medicines that cannot be parallel exported from the UK because they are needed for UK patients.
Alliance Pharmaceuticals Ltd has informed the MHRA that there are possible side effects not reported on the Patient Information Leaflet.
Aventis Pharma Limited t/a Sanofi has informed the MHRA that a change to the Patient Information Leaflet concerning possible side effects for Rifadin (rifampicin) 150mg Capsules has not been implemented by the required timeline.
How the Medicines and Healthcare products Regulatory Agency (MHRA) makes decisions on what is a medicine or medical device (borderline products).
Decisions made by MHRA following investigations into complaints about advertising for licensed medicines.
List of field safety notices (FSNs) from medical device manufacturers from 7 October to 11 October
Helps manufacturers and healthcare professionals understand the definition of assistive technology and the difference between medical devices and aids to daily living.
Comply with good manufacturing practice (GMP) and good distribution practice (GDP), and prepare for an inspection.
Pharmacovigilance system requirements if there is a no-deal Brexit.
The UK has a unique opportunity to lead the field in Life Sciences, with an exciting and important role for the MHRA.
Importing investigational medicinal products for use in clinical trials if there's a no-deal Brexit.
The MHRA will review applications for orphan designation at the time of a marketing authorisation (MA) or variation application.
Manufactured by Baxter – Communication error alarms may result in unintentional delay and interruption of treatment due to system shutdown.
How the MHRA will assess Marketing Authorisation Applications (MAA) for medicines referred under Article 29 if there's a no-deal Brexit.
Manufactured by Teleflex Medical – disconnection can result in inadequate oxygenation and ventilation requiring medical intervention to avoid hypoxia, severe neurological injury or death.
This report (UK VARSS) provides the details of UK veterinary antibiotic resistance and sales surveillance.
This report (UK VARSS) provides the details of UK veterinary antibiotic resistance and sales surveillance.
Launch of national application forms for a marketing authorisation.
Availability of veterinary medicines after Brexit.
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
As a vet or pharmacist, you must follow legal requirements when working with controlled drugs in veterinary medicine.
Application form to vary a national marketing authorisation.
Application form to renew a national marketing authorisation.
This form should be used to apply for a new marketing authorisation.
Reporting against VMD published standards up to 30 September 2019.
Details of the improvement notice issued to Castlehill Veterinary Clinic, Dungannon, County Tyrone. Published in August 2019.
Details of seizure notice served to Mr Yearling, Plymouth. Published in October 2019.
Details of seizure of veterinary medicines at Border Force, Stansted Airport, following a routine search of freight. Published in October 2019
Successful new format for joint VMD, Veterinary Products Committee open meeting and Pharmaceutical Industry Information Event at the VMD on 25 September 2019
Details of the improvement notice served to Johnston Agri Supplies, Enniskillen, County Fermanagh. Published in October 2019.
Apply for an import certificate to import a medicinal product into the UK for veterinary use.
Details of seizure notice served to Essex Vets, South Woodham, Essex.
Availability of flunixin solutions for injection.
Residues of veterinary medicines in food 2019 surveillance results.
We are updating the system to simplify and streamline the application process.
The Progenics drug is currently not approved for any indication outside of the US.
24% of asthma patients have difficult-to-treat or severe versions of the disease.
Only half of patients who are diagnosed as young onset patients are offered a genetic test on diagnosis.
UPS, DFDS and Biocair will handle express freight services to deliver medicines and medical products within 24 to 48 hours in the event of a no-deal Brexit.
AstraZeneca and Daiichi Sankyo's trastuzumab deruxtecan has taken a step closer to US approval having been accepted for priority review by the US Food and Drug Administration (FDA) for breast cancer.
The 2019 Medical & Scientific Excellence Awards will be closing for entry on 31st October.
58,000 more children were recorded as obese than last year.
The system aims to help paramedics on the ground to make the right clinical decisions instead of taking the patient to A&E.
There is currently a “critical need” for additional treatment options for atopic dermatitis.
Professor Sir Mike Richards makes several recommendations, with a key focus on improving uptake.
The campaign is aimed at students who don't know what they could be buying online.
The approval marks the first new class of acute migraine treatment approved by the FDA in more than two decades.
Performance statistics throughout the last year have shown “strain on an already stretched system."
The process could pave the way for more rapid delivery of individualised treatments.
The study is still ongoing, with patients participating in a 48-week safety follow-up period.
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available
